ストックスクリーナーアプリを入手
17.01
2.80%
-0.49
前日終値:
$17.50
開ける：
$17.3
24時間の取引高:
3,596
Relative Volume:
0.42
時価総額：
$43.42M
収益：
$5.02M
当期純損益:
$-18.31M
株価収益率:
-3.755
EPS:
-4.53
ネットキャッシュフロー:
$-23.40M
1週間 パフォーマンス:
+12.87%
1か月 パフォーマンス:
+2.84%
6か月 パフォーマンス:
+23.26%
1年 パフォーマンス:
-16.98%
1日の値動き範囲:
$17.01
$17.96
1週間の範囲:
$14.83
$17.96
52週間の値動き範囲:
$12.12
$26.99
Vtv Therapeutics Inc Stock (VTVT) Company Profile
VTVT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VTVT
Vtv Therapeutics Inc
|
17.01 | 43.42M | 5.02M | -18.31M | -23.40M | -4.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.85 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.94 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.24 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
250.30 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Vtv Therapeutics Inc Stock (VTVT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2019-05-30 | 開始されました | H.C. Wainwright | Buy |
| 2018-04-10 | ダウングレード | Stifel | Buy → Hold |
| 2018-03-08 | 開始されました | ROTH Capital | Buy |
| 2018-02-08 | 開始されました | Northland Capital | Outperform |
| 2016-09-26 | 開始されました | H.C. Wainwright | Buy |
| 2015-09-04 | 開始されました | Canaccord Genuity | Buy |
| 2015-08-24 | 開始されました | Piper Jaffray | Overweight |
| 2015-08-24 | 開始されました | Stifel | Buy |
すべてを表示
Vtv Therapeutics Inc (VTVT) 最新ニュース
Trading (VTVT) With Integrated Risk Controls - news.stocktradersdaily.com
VTv Therapeutics Inc.(NasdaqCM: VTVT) dropped from Russell 3000E Value Index - MarketScreener
vTv Therapeutics Holds 2025 Annual Stockholders Meeting - TipRanks
Transcript : VTv Therapeutics Inc.Special Call - MarketScreener
vTv Therapeutics to Participate in the H.C. Wainwright “HCW@Home” Series - GlobeNewswire
vTv Therapeutics Showcases First-in-Class Type 1 Diabetes Treatment at HC Wainwright | VTVT Stock News - Stock Titan
(VTVT) Trading Signals - news.stocktradersdaily.com
(VTVT) Technical Data - news.stocktradersdaily.com
vTv resumes Phase III oral T1D drug study - The Pharma Letter
vTv Therapeutics appoints new CFO amid Phase 3 trial By Investing.com - Investing.com South Africa
vTv Therapeutics Appoints New CFO Amidst Phase 3 Trial - TipRanks
vTv Therapeutics Appoints Michael Tung, M.D., MBA, As Chief Financial Officer - citybiz
VTv Therapeutics Names Michael Tung as Finance Chief - marketscreener.com
vTv Therapeutics (VTVT) Appoints New CFO | VTVT Stock News - GuruFocus
vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Fina - GuruFocus
VTv Therapeutics Names Michael Tung CFO, Effective Immediately - Nasdaq
vTv Therapeutics appoints new CFO amid Phase 3 trial - Investing.com
vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief - GlobeNewswire
vTv Therapeutics Advances First-in-Class Oral Type 1 Diabetes Drug as New CFO Joins - Stock Titan
VTv Therapeutics: Q1 Earnings Snapshot - Bluefield Daily Telegraph
How to Take Advantage of moves in (VTVT) - news.stocktradersdaily.com
vTv Therapeutics Highlights Cadisegliatin’s Potential for Diabetes - TipRanks
VTVT Advances Cadisegliatin Program with Phase 3 Study | VTVT St - GuruFocus
vTv Therapeutics advances type 1 diabetes trial By Investing.com - Investing.com South Africa
vTv Therapeutics Inc Reports Q1 2025 EPS of -$0.77, Beating Estimates; Net Loss at $5.1 Million - GuruFocus
vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update - The Manila Times
vTv Therapeutics Accelerates Timeline for First-Ever Oral Type 1 Diabetes Drug as Phase 3 Trial Advances - Stock Titan
VTV Therapeutics Announces Reinitiation Of Screening In CATT1 Phase 3 Trial - marketscreener.com
vTv Therapeutics advances type 1 diabetes trial - Investing.com Australia
VTv Therapeutics Resumes Cadisegliatin Testing in Type 1 Diabetes - marketscreener.com
vTv Therapeutics (VTVT) Resumes Phase 3 Trial for Diabetes Treat - GuruFocus
vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes | VTVT Stock New - GuruFocus
vTv Therapeutics (VTVT) Resumes Phase 3 Trial for Diabetes Treatment | VTVT Stock News - GuruFocus
vTv Therapeutics Announces Reinitiation of CATT1 Phase 3 Trial for Cadisegliatin, Shortens Duration to Expedite Topline Data Expected in 2026 - Nasdaq
vTv Therapeutics Announces Reinitiation of Screening in - GlobeNewswire
vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes - Stock Titan
How the (VTVT) price action is used to our Advantage - news.stocktradersdaily.com
vTv Therapeutics Inc expected to post a loss of 81 cents a shareEarnings Preview - TradingView
Geode Capital Management LLC Has $158,000 Holdings in vTv Therapeutics Inc. (NASDAQ:VTVT) - Defense World
vTv Therapeutics (VTVT) to Release Quarterly Earnings on Thursday - Defense World
vTv Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:VTVT - Benzinga
vTv Therapeutics (NASDAQ:VTVT) Coverage Initiated at StockNews.com - Defense World
vTv Therapeutics Appoints Barry Brown as Interim CFO - MSN
vTv Therapeutics (NASDAQ:VTVT) Coverage Initiated at HC Wainwright - Defense World
Q1 Earnings Forecast for VTVT Issued By HC Wainwright - Defense World
Vtv Therapeutics Inc (VTVT) 財務データ
収益
当期純利益
現金流量
EPS
2.10%
1.57%
大文字化:
|
ボリューム (24 時間):